Press Releases

04Jun, 2019

Intersect ENT Announces Publication of a Pooled Analysis of the SINUVA Sinus Implant for Nasal Polyps

June 4th, 2019|

06May, 2019

Intersect ENT Announces CEO Transition Plan

May 6th, 2019|

17Dec, 2018

Intersect ENT Announces First Patient Enrolled in ASCEND Study of Investigational Drug-Coated Sinus Balloon

December 17th, 2018|

15Nov, 2018

Intersect ENT Announces Publication of Pooled Analysis of Steroid Releasing Implants in Patients Following Frontal Sinus Surgery

November 15th, 2018|

29Oct, 2018

Intersect ENT Announces Executive Team Appointments

October 29th, 2018|

02Apr, 2018

Intersect ENT Announces Launch of SINUVA™ Sinus Implant, a New In-Office Treatment Option for Recurrent Nasal Polyps

April 2nd, 2018|

22Jan, 2018

Intersect ENT Announces Publication of Randomized Pivotal Study of the SINUVA™ Sinus Implant, a New In-Office Treatment Option for Recurrent Nasal Polyps

January 22nd, 2018|

11Dec, 2017

Intersect ENT Announces FDA Approval of SINUVA™ Sinus Implant

December 11th, 2017|

06Nov, 2017

FDA Performs Pre-Approval Inspection of Intersect ENT’s Menlo Park Facility

November 6th, 2017|

02Nov, 2017

Intersect ENT Announces a Pivotal Study Publication of PROPEL® Contour Steroid Releasing Sinus Implant

November 2nd, 2017|

09Oct, 2017

Intersect ENT Announces Presentation of Results from RESOLVE II, a Pivotal Phase III Study Evaluating the Safety and Efficacy of SINUVA™, an Investigational Steroid Releasing Sinus Implant

October 9th, 2017|

09Sep, 2017

Intersect ENT Announces Presentation of a Meta-Analysis from Two Randomized Studies Evaluating the Safety and Efficacy of SINUVA™, an Investigational Steroid Releasing Sinus Implant

September 9th, 2017|

20Jul, 2017

Teresa L. Kline Joins Intersect ENT’s Board of Directors

July 20th, 2017|

22May, 2017

Intersect ENT Announces PDUFA Date for Office-Based SINUVA Steroid Releasing Sinus Implant

May 22nd, 2017|

08Mar, 2017

Intersect ENT Submits New Drug Application to FDA for Office-Based RESOLVE Steroid Releasing Implant for Recurrent Chronic Sinus Disease

March 8th, 2017|

24Feb, 2017

Intersect ENT Announces FDA Approval of Newest Steroid Releasing Implant, PROPEL® Contour, for Use in Treating the Frontal and Maxillary Sinuses

February 24th, 2017|

2016 Press Releases

17Oct, 2016

Intersect ENT Announces Positive Clinical Results of Pivotal Study of RESOLVE In-Office Steroid Releasing Implant

October 17th, 2016|

19Sep, 2016

Intersect ENT Announces American Rhinologic Society Endorsement of the Use of Drug Eluting Sinus Implants

September 19th, 2016|

29Aug, 2016

Intersect ENT Announces Positive Coverage Decision by CareFirst BlueCross BlueShield to Expand Access to PROPEL Steroid Releasing Implants to More Patients

August 29th, 2016|

01Aug, 2016

Intersect ENT Announces FDA Submission of NOVA Bioabsorbable Steroid Releasing Implant for Patients with Chronic Sinus Disease

August 1st, 2016|

11Jul, 2016

Intersect ENT Announces Publication of PROGRESS Study of Steroid Releasing Implant in Patients with Frontal Sinus Disease

July 11th, 2016|

01Jun, 2016

Intersect ENT Announces Completion of Enrollment in RESOLVE II Clinical Trial of New In-Office Implant for Recurrent Chronic Sinusitis

June 1st, 2016|

16May, 2016

Intersect ENT Announces Positive Clinical Results from Pivotal Study of Newest Steroid Releasing Sinus Implant

May 16th, 2016|

23Mar, 2016

Intersect ENT Announces FDA Approval of Additional Indication for PROPEL® mini Sinus Implant

March 23rd, 2016|

24Feb, 2016

Intersect ENT Appoints David Lehman General Counsel

February 24th, 2016|

02Feb, 2016

Intersect ENT Announces NUB Status 1 Designation for PROPEL Sinus Implant in Germany

February 2nd, 2016|

2015 Press Releases

17Nov, 2015

Intersect ENT Recognized for Gender Diversity by Watermark and UC Davis

November 17th, 2015|

10Nov, 2015

Intersect ENT Announces Data Further Demonstrating Health Economic Value of PROPEL Steroid Releasing Implants

November 10th, 2015|

21Oct, 2015

Intersect ENT Announces Publication of Position Statement from AAO-HNS on Use of Biomaterials

October 21st, 2015|

30Sep, 2015

Intersect ENT Announces FDA Submission to Seek Expanded Indication of PROPEL Mini Steroid Releasing Implant to Treat Patients with Frontal Sinus Disease

September 30th, 2015|

28Sep, 2015

Intersect ENT Announces Positive Clinical Results from Three Studies Evaluating Steroid Releasing Implants Placed in the Physician’s Office

September 28th, 2015|

17Aug, 2015

Intersect ENT Announces Positive Preliminary Clinical Results for the PROPEL Mini Steroid Releasing Implant in Patients with Frontal Sinus Disease

August 17th, 2015|

08Jul, 2015

Intersect ENT Enrolls First Patient in Pivotal Study to Evaluate the NOVA Sinus Implant

July 8th, 2015|

08Jun, 2015

Intersect ENT Announces Exercise of Underwriters’ Option and the Closing of Its Public Offering

June 8th, 2015|

02Jun, 2015

Intersect ENT Announces Upsizing and Pricing of Public Offering

June 2nd, 2015|

04May, 2015

Intersect ENT Announces Positive Coverage Decision by Health Care Service Corporation

May 4th, 2015|

10Apr, 2015

Intersect ENT Appoints Kieran Gallahue and Tony Vernon to Board of Directors

April 10th, 2015|

2014 Press Releases

29Dec, 2014

Intersect ENT Announces Enrollment of First Patient In Phase III Study of In-Office Treatment for Recurrent Chronic Sinusitis

December 29th, 2014|

24Oct, 2014

Intersect ENT Named “Fastest Growing” in San Francisco and Silicon Valley

October 24th, 2014|

08Oct, 2014

Intersect ENT Announces Publication of Positive Data from Three Studies of Company’s Drug-Eluting Sinus Implants

October 8th, 2014|

01Oct, 2014

Intersect ENT Added To Russell 2000 Index

October 1st, 2014|

22Sep, 2014

Intersect ENT Announces Positive Data from Clinical Trial of New In-Office Implant for Recurrent Chronic Sinusitis

September 22nd, 2014|

17Sep, 2014

Intersect ENT Enrolls First Patient in Clinical Study to Expand Access to PROPEL Treatment to Broader Patient Population

September 17th, 2014|

11Aug, 2014

Study Indicates Cost Effectiveness of Intersect ENT’s PROPEL Implant for Chronic Sinusitis Study Author Assesses Significant Productivity Loss from Chronic Sinusitis

August 11th, 2014|

24Jul, 2014

Intersect ENT Announces Pricing of its Initial Public Offering

July 24th, 2014|

11Jul, 2014

Intersect ENT Announces Appointment of Cynthia L. Lucchese to Board of Directors

July 11th, 2014|

01Jun, 2014

Intersect ENT Announces Appointment of Chief Financial Officer Jeryl Hilleman

June 1st, 2014|

23Jan, 2014

Intersect ENT Named One of Forbes Magazine’s “America’s Most Promising Companies” of 2014

January 23rd, 2014|

08Jan, 2014

Intersect ENT to Present at the 32nd Annual JP Morgan Healthcare Conference

January 8th, 2014|

2013 Press Releases

15Oct, 2013

Intersect ENT Named One of the “Fierce 15” Most Promising Private Companies by FierceMedicalDevices

October 15th, 2013|

30Sep, 2013

Intersect ENT Announces Positive Results from Pilot Study of Novel In-Office Implant for Chronic Sinusitis Patients

September 30th, 2013|

03May, 2013

Intersect ENT President and CEO Lisa Earnhardt Named One of Bay Area’s “Most Influential Women in Business”

May 3rd, 2013|

03Apr, 2013

Intersect ENT Vice President Susan Stimson Honored As “Marketer That Matters”

April 3rd, 2013|

25Feb, 2013

Intersect ENT Raises $30 Million Funds to Fuel Commercial Expansion and Development of Next Generation Products for Chronic Sinusitis Sufferers

February 25th, 2013|

31Jan, 2013

Intersect ENT Initiates U.S. Clinical Study of a Novel In-Office Treatment for Chronic Sinusitis Patients

January 31st, 2013|

2012 Press Releases

06Nov, 2012

Intersect ENT Announces FDA Approval PROPEL Mini, Allowing More Chronic Sinusitis Patients to Benefit from Localized Drug Delivery

November 6th, 2012|

06Jun, 2012

Groundbreaking Clinical Evidence Demonstrates Benefit of PROPEL Implant for Chronic Sinusitis Patients

June 6th, 2012|

17Apr, 2012

Intersect ENT Quadruples Operation Size with Expansion to New Facility in Menlo Park, Calif.

April 17th, 2012|

2011 Press Releases

13Sep, 2011

Intersect ENT Announces Positive Data from Pivotal Study of PROPEL Implant, Showing Significantly Improved Outcomes For Sinus Surgery

September 13th, 2011|

15Aug, 2011

Intersect ENT Announces U.S. Food and Drug Administration Approval for First Drug Releasing Implant for Chronic Sinusitis Patients

August 15th, 2011|

2010 Press Releases

01Nov, 2010

Intersect ENT Closes Series C Financing, Recognized for Clinical Science

November 1st, 2010|

07Jan, 2010

Sinexus Changes Name To Intersect ENT, Initiates Pivotal Study

January 7th, 2010|

2008 Press Releases

05Jun, 2008

Sinexus Welcomes New CEO and Completes Series B

June 5th, 2008|